Latest news and press releases about Enliven Therapeutics, Inc. (ELVN): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Enliven Therapeutics, Inc. is a biopharmaceutical enterprise, currently in the clinical development phase, dedicated to discovering and advancing small molecule therapeutic agents aimed at combating cancer. Its pipeline includes ELVN-001, a small molecule kinase inhibitor currently in a Phase 1 clinical trial for adult patients with chronic myeloid leukemia.
Price
| Price | $49.12 |
| Market Cap | $3.5B |
| Exchange | NASDAQ |
| Country | US |
Related companies: ATAI · DNTH · IMTX · INBX · NKTR · ORIC · PGEN
Explore sector: Healthcare · Biotechnology
More sections of ELVN: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks